Originally formed in 1992 and based in Edinburgh, Archangels is a prominent business angel syndicate which has been at the forefront of early stage investing in Scotland for more than a quarter of a century.

Latest News

  • New Archangels Board Member: Tim Allan

    Scottish Chambers of Commerce President Joins Archangels Board Tim Allan is joining the board of Archangels. He succeeds Alastair Salvesen CBE, whose retirement from the Archangels board, on which he has served for 10 years, is being announced at our annual Chorus event for investors and investee companies which takes place this evening (14th March, […]

  • Optoscribe Release New Ultra-High Speed 3D Photonic Manufacturing

    Our portfolio company Optoscribe Ltd has this week announced the release of its 3rd generation ultra-high-speed 3D photonic component manufacturing system and the expansion of its cleanroom within its state-of-the-art facility in Livingston, UK. The company, a world-leader in the delivery of high-volume laser-based manufacturing of 3D photonic integrated circuits, has also increased its headcount by […]

  • Blackford Analysis Recognised with F&S Visionary Innovation Leadership Award

    Our portfolio company Blackford Analysis, the medical imaging platform, announced that it has been recognised with the 2019 Visionary Innovation Leadership Award from analyst firm Frost & Sullivan. The healthcare technology company won the award for best practices in medical imaging artificial intelligence (AI) marketplace solutions. Blackford Platform™ provides centralised access to a marketplace of medical imaging […]

  • Optoscribe and Sumitomo Electric Announce Strategic Cooperation

      Our portfolio company Optoscribe and Sumitomo Electric have announced a strategic cooperation to deliver multicore fiber components.  Optoscribe, a world-leading supplier of 3D glass-based integrated photonics components and Sumitomo Electric Industries, a world-class optical fiber cable and component manufacturing technology supplier, are delighted to announce the formation of a strategic cooperation to provide multicore […]

  • Investigational New Drug Applications Cleared for MGB BioPharma

    Our portfolio company MGB BioPharma, a biopharmaceutical company who is developing a novel class of anti-infectives, to address the major global problem of antibiotic resistance, has today announced that the Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND/CTA) for its lead candidate. MGB-BP-3 is a novel antibiotic that targets Clostridium difficile-Associated Diarrhoea (CDAD).  The […]

  • Archangels Leads on Another Record Year

    Another Record Year of Investment for Archangels 2018 has been another highly active year for Archangels, we have led a record breaking £22.4m of investment in Scottish tech and life sciences businesses.  Including £10.9m of our members’ cash in 10 investment rounds across the year, with co-investment of £9.4m from investment partners including Scottish Enterprise’s […]

Company portfolio

  • Archangel Investors Ltd
  • Archangel Investors Ltd
  • Archangel Investors Ltd

See our ‘Impact evaluation of activities report’ by the Hunter Centre for Entrepreneurship at The University of Strathclyde.